Comparative Study of the Efficacy, Safety, and Immunogenicity of CMAB015 and Secukinumab in Adult Patients With Moderate-severe Chronic Plaque Psoriasis
Latest Information Update: 20 Sep 2024
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Taizhou Mabtech Pharmaceuticals
Most Recent Events
- 13 Sep 2024 Status changed from not yet recruiting to recruiting.
- 08 May 2024 New trial record